{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T05:18:57Z","timestamp":1787462337506,"version":"build-2736575974"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]},{"name":"La Roche Posay"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04209-0","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T06:26:11Z","timestamp":1769581571000},"page":"2603-2624","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody\u2013drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9919-7485","authenticated-orcid":false,"given":"Margarita","family":"Majem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Molina Mata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ander","family":"Mayor Ibarguren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Zafra Poves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Requena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1468-1375","authenticated-orcid":false,"given":"Francisco de Asis","family":"Aparisi Aparisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1608-8820","authenticated-orcid":false,"given":"Cristina","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5889-0382","authenticated-orcid":false,"given":"Ana","family":"Blasco Cordellat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3121-5667","authenticated-orcid":false,"given":"Azael","family":"Freites-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onofre","family":"Sanmartin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"4209_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"4209_CR2","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","volume":"83","author":"AN Geisler","year":"2020","unstructured":"Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, et al. Immune checkpoint inhibitor\u2013related dermatologic adverse events. J Am Acad Dermatol. 2020;83(5):1255\u201368. https:\/\/doi.org\/10.1016\/j.jaad.2020.03.132.","journal-title":"J Am Acad Dermatol"},{"key":"4209_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00520-007-0318-8","volume":"16","author":"M Hackbarth","year":"2008","unstructured":"Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W, Sehouli J. Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women\u2019s cancers. results of a prospective study. Support Care Cancer. 2008;16:267\u201373. https:\/\/doi.org\/10.1007\/s00520-007-0318-8.","journal-title":"Support Care Cancer"},{"key":"4209_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.humpath.2023.04.014","volume":"140","author":"D Haynes","year":"2023","unstructured":"Haynes D, Morgan EE, Chu EY. Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings. Hum Pathol. 2023;140:129\u201343. https:\/\/doi.org\/10.1016\/j.humpath.2023.04.014.","journal-title":"Hum Pathol"},{"key":"4209_CR5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/S40257-017-0336-3","volume":"19","author":"V Sibaud","year":"2018","unstructured":"Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19:345\u201361. https:\/\/doi.org\/10.1007\/S40257-017-0336-3.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"4209_CR6","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jaad.2018.03.055","volume":"80","author":"A Freites-Martinez","year":"2019","unstructured":"Freites-Martinez A, Shapiro J, Goldfarb S, Nangia J, Jimenez JJ, Paus R, et al. Hair disorders in patients with cancer. J Am Acad Dermatol. 2019;80(5):1179\u201396. https:\/\/doi.org\/10.1016\/j.jaad.2018.03.055.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"4209_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.alit.2022.01.001","volume":"71","author":"N Okiyama","year":"2022","unstructured":"Okiyama N, Tanaka R. Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergol Int. 2022;71(2):169\u201378. https:\/\/doi.org\/10.1016\/j.alit.2022.01.001.","journal-title":"Allergol Int"},{"key":"4209_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/JNCICS\/PKAD069","author":"Y Suzuki","year":"2023","unstructured":"Suzuki Y, Zhou S, Ota Y, Harrington M, Miyagi E, Takagi H, et al. Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis. JNCI Cancer Spectr. 2023. https:\/\/doi.org\/10.1093\/JNCICS\/PKAD069.","journal-title":"JNCI Cancer Spectr"},{"key":"4209_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/S40257-018-0384-3","volume":"19","author":"M Lacouture","year":"2018","unstructured":"Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19:31\u20139. https:\/\/doi.org\/10.1007\/S40257-018-0384-3.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"4209_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","volume":"32","author":"ME Lacouture","year":"2021","unstructured":"Lacouture ME, Sibaud V, Gerber PA, van den Hurk C, Fern\u00e1ndez-Pe\u00f1as P, Santini D, et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO clinical practice guidelines\u2606. Ann Oncol. 2021;32(2):157\u201370. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.005.","journal-title":"Ann Oncol"},{"key":"4209_CR11","first-page":"48","volume":"12","author":"DL Stanculeanu","year":"2017","unstructured":"Stanculeanu DL, Zob D, Toma OC, Georgescu B, Papagheorghe L, Mihaila RI. Cutaneous Toxicities of Molecular Targeted therapies. Maedica (Bucur). 2017;12:48.","journal-title":"Maedica (Bucur)"},{"key":"4209_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000112795","volume":"72","author":"SL Boone","year":"2008","unstructured":"Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology. 2008;72:152\u20139. https:\/\/doi.org\/10.1159\/000112795.","journal-title":"Oncology"},{"key":"4209_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1200\/EDBK_289911","volume":"40","author":"A Deutsch","year":"2020","unstructured":"Deutsch A, Leboeuf NR, Lacouture ME, McLellan BN. Dermatologic adverse events of systemic anticancer therapies: cytotoxic chemotherapy, targeted therapy, and immunotherapy. Am Soc Clin Oncol Educ Book. 2020;40:485\u2013500. https:\/\/doi.org\/10.1200\/EDBK_289911.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"4209_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000479198","volume":"53","author":"O Sanmart\u00edn","year":"2017","unstructured":"Sanmart\u00edn O. Skin manifestations of targeted antineoplastic therapy. Curr Probl Dermatol (Switzerland) S Karger AG. 2017;53:93\u2013104. https:\/\/doi.org\/10.1159\/000479198.","journal-title":"Curr Probl Dermatol (Switzerland). S. Karger AG"},{"key":"4209_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2015.1004969","author":"M Holcmann","year":"2015","unstructured":"Holcmann M, Sibilia M. Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol Cell Oncol. 2015. https:\/\/doi.org\/10.1080\/23723556.2015.1004969.","journal-title":"Mol Cell Oncol"},{"key":"4209_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.804212","author":"Y Li","year":"2022","unstructured":"Li Y, Fu R, Jiang T, Duan D, Wu Y, Li C, et al. Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/FONC.2022.804212.","journal-title":"Front Oncol"},{"key":"4209_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2024.1457226","author":"J Qian","year":"2024","unstructured":"Qian J, Wan J, Yao Q, Chen Y, Ling T, Zhang Y, et al. Cutaneous adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. Front Pharmacol. 2024. https:\/\/doi.org\/10.3389\/FPHAR.2024.1457226.","journal-title":"Front Pharmacol"},{"key":"4209_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS15143658","author":"P Sollena","year":"2023","unstructured":"Sollena P, Vasiliki N, Kotteas E, Stratigos AJ, Fattore D, Orlandi A, et al. Cyclin-dependent kinase 4\/6 inhibitors and dermatologic adverse events: results from the EADV task force \u201cdermatology for cancer patients\u201d international study. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/CANCERS15143658.","journal-title":"Cancers (Basel)"},{"key":"4209_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000486338","volume":"94","author":"F Petrelli","year":"2018","unstructured":"Petrelli F, Ardito R, Ghidini A, Zaniboni A, Ghidini M, Barni S, et al. Different toxicity of cetuximab and panitumumab in metastatic colorectal cancer treatment: a systematic review and meta-analysis. Oncology. 2018;94:191\u20139. https:\/\/doi.org\/10.1159\/000486338.","journal-title":"Oncology"},{"issue":"2","key":"4209_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/J.CLCC.2017.12.004","volume":"17","author":"ME Lacouture","year":"2018","unstructured":"Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E, et al. Dermatologic toxicity occurring during anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: a systematic review. Clin Colorectal Cancer. 2018;17(2):85\u201396. https:\/\/doi.org\/10.1016\/J.CLCC.2017.12.004.","journal-title":"Clin Colorectal Cancer"},{"key":"4209_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS16020350","author":"M Santorsola","year":"2024","unstructured":"Santorsola M, Capuozzo M, Nasti G, Sabbatino F, Di Mauro A, Di Mauro G, et al. Exploring the spectrum of VEGF inhibitors\u2019 toxicities from systemic to intra-vitreal usage in medical practice. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/CANCERS16020350.","journal-title":"Cancers (Basel)"},{"key":"4209_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.lungcan.2022.09.012","volume":"173","author":"C Basse","year":"2022","unstructured":"Basse C, Chabanol H, Bonte PE, Fromantin I, Girard N. Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach. Lung Cancer. 2022;173:116\u201323. https:\/\/doi.org\/10.1016\/j.lungcan.2022.09.012.","journal-title":"Lung Cancer"},{"issue":"6","key":"4209_CR23","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jaad.2024.08.036","volume":"91","author":"C Gronbeck","year":"2024","unstructured":"Gronbeck C, Hadfield MJ, Grant-Kels JM. Dermatologic toxicities of antibody-drug conjugates. J Am Acad Dermatol. 2024;91(6):1177\u201388. https:\/\/doi.org\/10.1016\/j.jaad.2024.08.036.","journal-title":"J Am Acad Dermatol"},{"key":"4209_CR24","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annder.2022.11.013","volume":"150","author":"V Sibaud","year":"2023","unstructured":"Sibaud V, Sollena P. Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: an updated review for clinical practice. Ann Dermatol Venereol. 2023;150:208\u201312. https:\/\/doi.org\/10.1016\/j.annder.2022.11.013.","journal-title":"Ann Dermatol Venereol"},{"key":"4209_CR25","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMOA0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947\u201357. https:\/\/doi.org\/10.1056\/NEJMOA0810699.","journal-title":"N Engl J Med"},{"key":"4209_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"F Shepherd","year":"2005","unstructured":"Shepherd F, Rodrigues Pereira J, Ciuleanu T, Huat Tan E, Hirsh V, Thonngprasert S, et al. Erlotinib in previously treated non\u2013small-cell lung cancer. New Engl J Med. 2005;353:123\u201332.","journal-title":"New Engl J Med"},{"key":"4209_CR27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA064320","volume":"5","author":"CE Geyer","year":"2008","unstructured":"Geyer CE, Forster J, Lindquist D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. Adv Breast Cancer. 2008;5:45. https:\/\/doi.org\/10.1056\/NEJMOA064320.","journal-title":"Adv Breast Cancer"},{"key":"4209_CR28","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:1454\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(17)30608-3.","journal-title":"Lancet Oncol"},{"key":"4209_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","volume":"17","author":"A Chan","year":"2016","unstructured":"Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17:367\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(15)00551-3.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4209_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMOA1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR -mutated advanced non\u2013small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325. https:\/\/doi.org\/10.1056\/NEJMOA1713137.","journal-title":"N Engl J Med"},{"key":"4209_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2018.00616","author":"S Uozumi","year":"2018","unstructured":"Uozumi S, Enokida T, Suzuki S, Nishizawa A, Kamata H, Okano T, et al. Predictive value of cetuximab-induced skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Front Oncol. 2018. https:\/\/doi.org\/10.3389\/FONC.2018.00616.","journal-title":"Front Oncol"},{"key":"4209_CR32","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"RG Amado","year":"2008","unstructured":"Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626\u201334. https:\/\/doi.org\/10.1200\/JCO.2007.14.7116.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4209_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","volume":"16","author":"JCH Yang","year":"2015","unstructured":"Yang JCH, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(14)71173-8.","journal-title":"Lancet Oncol"},{"key":"4209_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.3005886","author":"BM Lichtenberger","year":"2013","unstructured":"Lichtenberger BM, Gerber PA, Holcmann M, Buhren BA, Amberg N, Smolle V, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med. 2013. https:\/\/doi.org\/10.1126\/SCITRANSLMED.3005886.","journal-title":"Sci Transl Med"},{"key":"4209_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/JNCI\/DJP439","volume":"102","author":"RE Eilers","year":"2010","unstructured":"Eilers RE, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst. 2010;102:47\u201353. https:\/\/doi.org\/10.1093\/JNCI\/DJP439.","journal-title":"J Natl Cancer Inst"},{"key":"4209_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE \u2013 Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. 2021;112:90\u20132. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009.","journal-title":"Actas Dermosifiliogr"},{"key":"4209_CR37","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2006.s.008","author":"R Perez-Soler","year":"2006","unstructured":"Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer. 2006. https:\/\/doi.org\/10.3816\/CLC.2006.s.008.","journal-title":"Clin Lung Cancer"},{"key":"4209_CR38","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/J.ADENGL.2015.05.014","volume":"106","author":"A Jaka","year":"2015","unstructured":"Jaka A, Guti\u00e9rrez-Rivera A, L\u00f3pez-Pesta\u00f1a A, del Alc\u00e1zar E, Zubizarreta J, Vildosola S, et al. Predictors of tumor response to cetuximab and panitumumab in 116 patients and a review of approaches to managing skin toxicity. Actas Dermosifiliogr. 2015;106:483\u201392. https:\/\/doi.org\/10.1016\/J.ADENGL.2015.05.014.","journal-title":"Actas Dermosifiliogr"},{"key":"4209_CR39","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/BJD.14756","volume":"175","author":"F Petrelli","year":"2016","unstructured":"Petrelli F, Borgonovo K, Cabiddu M, Coinu A, Ghilardi M, Lonati V, et al. Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis. Br J Dermatol. 2016;175:1166\u201374. https:\/\/doi.org\/10.1111\/BJD.14756.","journal-title":"Br J Dermatol"},{"key":"4209_CR40","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ad.2015.05.001","volume":"106","author":"O Sanmartin Jim\u00e9nez","year":"2015","unstructured":"Sanmartin Jim\u00e9nez O. Management of epidermal growth factor inhibitor-induced papulopustular rash: The dermatologist\u2019s role. Actas Dermosifiliogr. 2015;106:447.","journal-title":"Actas Dermosifiliogr"},{"key":"4209_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/S12916-014-0203-5","author":"WX Qi","year":"2014","unstructured":"Qi WX, Fu S, Zhang Q, Guo XM. Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: A systematic review and meta-analysis. BMC Med. 2014. https:\/\/doi.org\/10.1186\/S12916-014-0203-5.","journal-title":"BMC Med"},{"key":"4209_CR42","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.jaad.2014.12.010","volume":"72","author":"J Valentine","year":"2015","unstructured":"Valentine J, Belum VR, Duran J, Ciccolini K, Schindler K, Wu S, et al. Incidence and risk of xerosis with targeted anticancer therapies. J Am Acad Dermatol. 2015;72:656\u201367.","journal-title":"J Am Acad Dermatol"},{"key":"4209_CR43","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/S40257-016-0197-1","volume":"17","author":"K Chanprapaph","year":"2016","unstructured":"Chanprapaph K, Rutnin S, Vachiramon V. Multikinase inhibitor-induced hand-foot skin reaction: a review of clinical presentation, pathogenesis, and management. Am J Clin Dermatol. 2016;17:387\u2013402. https:\/\/doi.org\/10.1007\/S40257-016-0197-1.","journal-title":"Am J Clin Dermatol"},{"key":"4209_CR44","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/1440-1681.12935","volume":"45","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Zhang X, Lou X, Chen M, Luo P, He Q. Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand\u2013foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis. Clin Exp Pharmacol Physiol. 2018;45:659\u201367. https:\/\/doi.org\/10.1111\/1440-1681.12935.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"4209_CR45","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","volume":"19","author":"ME Lacouture","year":"2008","unstructured":"Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008;19:1955\u201361. https:\/\/doi.org\/10.1093\/annonc\/mdn389.","journal-title":"Ann Oncol"},{"key":"4209_CR46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/CED.12694","volume":"41","author":"VR Belum","year":"2016","unstructured":"Belum VR, Serna-Tamayo C, Wu S, Lacouture ME. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: A meta-analysis. Clin Exp Dermatol. 2016;41:8\u201315. https:\/\/doi.org\/10.1111\/CED.12694.","journal-title":"Clin Exp Dermatol"},{"key":"4209_CR47","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","volume":"26","author":"B McLellan","year":"2015","unstructured":"McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E. Regorafenib-associated hand-foot skin reaction: Practical advice on diagnosis, prevention, and management. Ann Oncol. 2015;26:2017\u201326. https:\/\/doi.org\/10.1093\/annonc\/mdv244.","journal-title":"Ann Oncol"},{"key":"4209_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/S00520-023-07830-3","author":"L Shou","year":"2023","unstructured":"Shou L, Chen J, Shao T, Zhang Y, Zhao S, Chen S, et al. Clinical characteristics, treatment outcomes, and prognosis in patients with MKIs-associated hand-foot skin reaction: a retrospective study. Support Care Cancer. 2023. https:\/\/doi.org\/10.1007\/S00520-023-07830-3.","journal-title":"Support Care Cancer"},{"key":"4209_CR49","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jaad.2023.11.054","volume":"90","author":"CW Lu","year":"2024","unstructured":"Lu CW, Yeh CN, Hsu HC, Chen CB, Yang TS, Pan YR, et al. Zinc supplementation is associated with improvement in hand-foot skin reaction in patients on vascular endothelial growth factor receptor-tyrosine kinase inhibitors: A cohort study. J Am Acad Dermatol. 2024;90:814\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2023.11.054.","journal-title":"J Am Acad Dermatol"},{"key":"4209_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/S12885-023-10864-9","author":"A Nishizawa","year":"2023","unstructured":"Nishizawa A, Shinozaki E, Wakatsuki T, Satoh T, Yamazaki N, Oyamada S, et al. Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin reactions: a single-arm trial. BMC Cancer. 2023. https:\/\/doi.org\/10.1186\/S12885-023-10864-9.","journal-title":"BMC Cancer"},{"key":"4209_CR51","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/J.AD.2018.10.019","volume":"110","author":"JF Mir-Bonaf\u00e9","year":"2019","unstructured":"Mir-Bonaf\u00e9 JF, Saceda-Corralo D, Va\u00f1\u00f3-Galv\u00e1n S. Reacciones capilares de las nuevas terapias diana dirigidas contra el c\u00e1ncer. Actas Dermosifiliogr. 2019;110:182\u201392. https:\/\/doi.org\/10.1016\/J.AD.2018.10.019.","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"4209_CR52","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/J.IJWD.2021.09.009","volume":"7","author":"S Huynh Dagher","year":"2021","unstructured":"Huynh Dagher S, Blom A, Chabanol H, Funck-Brentano E. Cutaneous toxicities from targeted therapies used in oncology: literature review of clinical presentation and management. Int J Womens Dermatol. 2021;7(5):615\u201324. https:\/\/doi.org\/10.1016\/J.IJWD.2021.09.009.","journal-title":"Int J Womens Dermatol"},{"key":"4209_CR53","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000004755","author":"A Rossi","year":"2025","unstructured":"Rossi A, Pan A, Menzer C, Lavin L, Aleissa S, Aleisa A, et al. Platelet-Rich plasma treatment for endocrine-induced alopecia and persistent chemotherapy-induced alopecia in breast cancer survivors: a randomized, controlled, pilot study. Dermatol Surg. 2025. https:\/\/doi.org\/10.1097\/DSS.0000000000004755.","journal-title":"Dermatol Surg"},{"key":"4209_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/DTH.14171","author":"L Antoury","year":"2020","unstructured":"Antoury L, Maloney NJ, Bach DQ, Goh C, Cheng K. Alopecia areata as an immune-related adverse event of immune checkpoint inhibitors: A review. Dermatol Ther. 2020. https:\/\/doi.org\/10.1111\/DTH.14171.","journal-title":"Dermatol Ther"},{"key":"4209_CR55","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4103\/IJT.IJT_72_17","volume":"10","author":"C Agrawal","year":"2018","unstructured":"Agrawal C, Goyal P, Doval Di, Dutta K, Domadia K, Kothiwal S. Eyelashes trichomegaly: an unusual side effect of gefitinib therapy. Int J Trichology. 2018;10:44\u20136. https:\/\/doi.org\/10.4103\/IJT.IJT_72_17.","journal-title":"Int J Trichology"},{"key":"4209_CR56","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1001\/JAMADERMATOL.2017.2106","volume":"153","author":"N Rivera","year":"2017","unstructured":"Rivera N, Boada A, Bielsa MI, Fern\u00e1ndez-Figueras MT, Carcereny E, Moran MT, et al. Hair repigmentation during immunotherapy treatment with an anti\u2013programmed cell death 1 and anti\u2013programmed cell death ligand 1 agent for lung cancer. JAMA Dermatol. 2017;153:1162\u20135. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2017.2106.","journal-title":"JAMA Dermatol"},{"key":"4209_CR57","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1684\/EJD.2016.2747","volume":"26","author":"E Dika","year":"2016","unstructured":"Dika E, Patrizi A, Ribero S, Fanti PA, Starace M, Melotti B, et al. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma. Eur J Dermatol. 2016;26:232\u20139. https:\/\/doi.org\/10.1684\/EJD.2016.2747.","journal-title":"Eur J Dermatol"},{"key":"4209_CR58","first-page":"13030","volume":"27","author":"G Nazzaro","year":"2020","unstructured":"Nazzaro G, Giacalone S, Bortoluzzi P, Veraldi S, Marzano AV. Erosive pustular dermatosis of the scalp induced by gefitinib: case and review of the literature. Dermatol Online J. 2020;27:13030.","journal-title":"Dermatol Online J"},{"key":"4209_CR59","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jdcr.2023.11.027","volume":"47","author":"MN George","year":"2024","unstructured":"George MN, Seervai RNH, Chon SY. Erosive pustular dermatosis-like eruption of the scalp secondary to amivantamab: a case series. JAAD Case Rep. 2024;47:72\u20139. https:\/\/doi.org\/10.1016\/j.jdcr.2023.11.027.","journal-title":"JAAD Case Rep"},{"key":"4209_CR60","doi-asserted-by":"publisher","first-page":"S347","DOI":"10.1016\/J.JTHO.2024.09.626","volume":"19","author":"BC Cho","year":"2024","unstructured":"Cho BC, Girard N, Sauder MB, Feldman J, Li W, Bozorgmehr F, et al. P3.12D.04 enhanced vs standard dermatologic management with Amivantamab-Lazertinib in advanced NSCLC: Phase 2 COCOON Study. J Thorac Oncol. 2024;19:S347. https:\/\/doi.org\/10.1016\/J.JTHO.2024.09.626.","journal-title":"J Thorac Oncol"},{"key":"4209_CR61","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2011.10.009","volume":"67","author":"BC Garden","year":"2012","unstructured":"Garden BC, Wu S, Lacouture ME. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. J Am Acad Dermatol. 2012;67:400\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2011.10.009.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"4209_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/ONCO.13552","volume":"26","author":"ME Lacouture","year":"2021","unstructured":"Lacouture ME, Sibaud V, Anadkat MJ, Kaffenberger B, Leventhal J, Guindon K, et al. Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines. Oncologist. 2021;26(2):e316\u201326. https:\/\/doi.org\/10.1002\/ONCO.13552.","journal-title":"Oncologist"},{"key":"4209_CR63","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/JDV.15121","volume":"33","author":"PH Ho","year":"2019","unstructured":"Ho PH, Lin IC, Yang X, Cho YT, Chu CY. Using a novel scoring system for paronychia related to oncologic treatments (SPOT) for assessing paronychia severity and its correlation with pain index and quality of life. J Eur Acad Dermatol Venereol. 2019;33:204\u201312. https:\/\/doi.org\/10.1111\/JDV.15121.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4209_CR64","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1001\/JAMADERMATOL.2017.4120","volume":"154","author":"X Cubir\u00f3","year":"2018","unstructured":"Cubir\u00f3 X, Planas-Ciudad S, Garcia-Muret MP, Puig L. Topical timolol for paronychia and pseudopyogenic granuloma in patients treatedwith epidermal growth factor receptor inhibitors and capecitabine. JAMA Dermatol. 2018;154:99\u2013100. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2017.4120.","journal-title":"JAMA Dermatol"},{"key":"4209_CR65","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1089\/WOUND.2013.0496","volume":"3","author":"RJ Bodnar","year":"2014","unstructured":"Bodnar RJ. Anti-angiogenic drugs: involvement in cutaneous side effects and wound-healing complication. Adv Wound Care. 2014;3:635\u201346. https:\/\/doi.org\/10.1089\/WOUND.2013.0496.","journal-title":"Adv Wound Care"},{"key":"4209_CR66","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/S12328-023-01802-0","volume":"16","author":"T Iwasa","year":"2023","unstructured":"Iwasa T, Adachi S, Ogiso H, Takada E, Mabuchi M, Suzuki Y, et al. Severe skin ulcer caused by taking lenvatinib after proton beam therapy. Clin J Gastroenterol. 2023;16:588\u201392. https:\/\/doi.org\/10.1007\/S12328-023-01802-0.","journal-title":"Clin J Gastroenterol"},{"key":"4209_CR67","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15862","volume":"48","author":"\u00c1 Mart\u00ednez-Dom\u00e9nech","year":"2021","unstructured":"Mart\u00ednez-Dom\u00e9nech \u00c1, Garc\u00eda-Legaz Mart\u00ednez M, P\u00e9rez-Pastor G, P\u00e9rez-Ferriols A. Lenvatinib-associated late-onset necrosis of a radiated skin graft. J Dermatol. 2021;48:e267\u20138. https:\/\/doi.org\/10.1111\/1346-8138.15862.","journal-title":"J Dermatol"},{"key":"4209_CR68","doi-asserted-by":"publisher","DOI":"10.1111\/AJD.14162","volume":"64","author":"SH Jeon","year":"2023","unstructured":"Jeon SH, Lee WJ, Won CH, Chang SE, Lee MW, Jung JM. Multiple lenvatinib-associated skin ulcers: a case report and literature review. Australas J Dermatol. 2023;64:e386\u20137. https:\/\/doi.org\/10.1111\/AJD.14162.","journal-title":"Australas J Dermatol"},{"issue":"2","key":"4209_CR69","doi-asserted-by":"publisher","DOI":"10.4103\/IJD.IJD_818_22","volume":"68","author":"A Samal","year":"2023","unstructured":"Samal A, Dixit N, Kar B, Mohapatra L. Tyrosine kinase inhibitors induced scrotal ulcerations: report of 2 cases. Indian J Dermatol. 2023;68(2):235. https:\/\/doi.org\/10.4103\/IJD.IJD_818_22.","journal-title":"Indian J Dermatol"},{"issue":"20","key":"4209_CR70","doi-asserted-by":"publisher","DOI":"10.1503\/CMAJ.191165","volume":"192","author":"T Kuntz","year":"2020","unstructured":"Kuntz T, Koushk-Jalali B, Kreuter A. Sunitinib-induced pyoderma gangrenosum-like skin ulcer. CMAJ. 2020;192(20):552. https:\/\/doi.org\/10.1503\/CMAJ.191165.","journal-title":"CMAJ"},{"issue":"5","key":"4209_CR71","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.jaad.2017.06.044","volume":"77","author":"J Dai","year":"2017","unstructured":"Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME. Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(5):902-910.e2. https:\/\/doi.org\/10.1016\/j.jaad.2017.06.044.","journal-title":"J Am Acad Dermatol"},{"key":"4209_CR72","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","volume":"72","author":"JB Macdonald","year":"2015","unstructured":"Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72:203\u201318. https:\/\/doi.org\/10.1016\/j.jaad.2014.07.032.","journal-title":"J Am Acad Dermatol"},{"key":"4209_CR73","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1001\/ARCHDERM.144.11.1525","volume":"144","author":"JT Hartmann","year":"2008","unstructured":"Hartmann JT, Kanz L. Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition. Arch Dermatol. 2008;144:1525\u20136. https:\/\/doi.org\/10.1001\/ARCHDERM.144.11.1525.","journal-title":"Arch Dermatol"},{"issue":"2","key":"4209_CR74","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/S11096-012-9615-5","volume":"34","author":"C Vignand-Courtin","year":"2012","unstructured":"Vignand-Courtin C, Martin C, Le Beller C, Mateus C, Barbault-Foucher S, Rieutord A. Cutaneous side effects associated with sunitinib: an analysis of 8 cases. Int J Clin Pharm. 2012;34(2):286\u20139. https:\/\/doi.org\/10.1007\/S11096-012-9615-5.","journal-title":"Int J Clin Pharm"},{"key":"4209_CR75","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1001\/2013.JAMADERMATOL.192","volume":"148","author":"D Giacchero","year":"2012","unstructured":"Giacchero D, Ramacciotti C, Arnault JP, Brassard M, Baudin E, Maksimovic L, et al. A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib. Arch Dermatol. 2012;148:1418\u201320. https:\/\/doi.org\/10.1001\/2013.JAMADERMATOL.192.","journal-title":"Arch Dermatol"},{"key":"4209_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS14194576","author":"N Hermann","year":"2022","unstructured":"Hermann N, Maul LV, Ameri M, Traidl S, Ziadlou R, Papageorgiou K, et al. Clinical presentation and prognostic features in patients with immunotherapy-induced vitiligo-like depigmentation: a monocentric prospective observational study. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/CANCERS14194576.","journal-title":"Cancers (Basel)"},{"key":"4209_CR77","first-page":"27","volume":"6","author":"PR Cohen","year":"2013","unstructured":"Cohen PR, Bedikian AY, Kim KB. Appearance of new vemurafenib-associated melanocytic nevi on normal-appearing skin: case series and a review of changing or new pigmented lesions in patients with metastatic malignant melanoma after initiating treatment with vemurafenib. J Clin Aesthet Dermatol. 2013;6:27\u201337.","journal-title":"J Clin Aesthet Dermatol"},{"key":"4209_CR78","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1634\/THEONCOLOGIST.2012-0333","volume":"18","author":"ME Lacouture","year":"2013","unstructured":"Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist. 2013;18:314\u201322. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2012-0333.","journal-title":"Oncologist"},{"key":"4209_CR79","doi-asserted-by":"publisher","DOI":"10.1111\/JDV.15818","volume":"33","author":"F Morgado","year":"2019","unstructured":"Morgado F, Calv\u00e3o J, Barata F, Gon\u00e7alo M. Phototoxic reaction to brigatinib \u2013 a new photosensitizing drug. J Eur Acad Dermatol Venereol. 2019;33:e491\u20132. https:\/\/doi.org\/10.1111\/JDV.15818.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"4209_CR80","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S1470-2045(20)30061-9","volume":"21","author":"JA Ledermann","year":"2020","unstructured":"Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(5):710\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(20)30061-9.","journal-title":"Lancet Oncol"},{"key":"4209_CR81","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/S10637-020-01035-9","volume":"39","author":"J Wu","year":"2021","unstructured":"Wu J, Liu D, Offin M, Lezcano C, Torrisi JM, Brownstein S, et al. Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers. Invest New Drugs. 2021;39:785\u201395. https:\/\/doi.org\/10.1007\/S10637-020-01035-9.","journal-title":"Invest New Drugs"},{"key":"4209_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2340\/00015555-3681","volume":"100","author":"Y Sakaguchi","year":"2020","unstructured":"Sakaguchi Y, Komori T, Aoki M, Otsuka A, Kabashima K, Matsushita S. Photosensitive dermatitis induced by nivolumab\/ipilimumab combination therapy in a patient with malignant melanoma. Acta Derm Venereol. 2020;100:1\u20132. https:\/\/doi.org\/10.2340\/00015555-3681.","journal-title":"Acta Derm Venereol"},{"key":"4209_CR83","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021;22:790\u2013800. https:\/\/doi.org\/10.1016\/S1470-2045(21)00139-X.","journal-title":"Lancet Oncol"},{"issue":"5","key":"4209_CR84","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1001\/JAMADERMATOL.2020.0208","volume":"156","author":"EP Sorensen","year":"2020","unstructured":"Sorensen EP, Thrush J, Bartlett NL, Rosman IS, Anadkat MJ, Jones HA. Diffuse telangiectatic rash associated with novel antibody drug conjugate therapies. JAMA Dermatol. 2020;156(5):601\u20133. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2020.0208.","journal-title":"JAMA Dermatol"},{"key":"4209_CR85","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/JDV.18200","volume":"36","author":"V Sibaud","year":"2022","unstructured":"Sibaud V. Anticancer treatments and photosensitivity. J Eur Acad Dermatol Venereol. 2022;36:51\u20138. https:\/\/doi.org\/10.1111\/JDV.18200.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4209_CR86","doi-asserted-by":"publisher","first-page":"9016","DOI":"10.1200\/JCO.2013.31.15_SUPPL.9016","volume":"31","author":"JS Cebon","year":"2013","unstructured":"Cebon JS, Flaherty K, Weber JS, Kim K, Infante JR, Daud A, et al. Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1\/2 inhibitor (MEKi) trametinib (T). J Clin Oncol. 2013;31:9016\u20139016. https:\/\/doi.org\/10.1200\/JCO.2013.31.15_SUPPL.9016.","journal-title":"J Clin Oncol"},{"key":"4209_CR87","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/NRCLINONC.2013.83","volume":"10","author":"GT Gibney","year":"2013","unstructured":"Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KSM. Paradoxical oncogenesis-the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol. 2013;10:390\u20139. https:\/\/doi.org\/10.1038\/NRCLINONC.2013.83.","journal-title":"Nat Rev Clin Oncol"},{"key":"4209_CR88","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1758834015616934","volume":"8","author":"Z Eroglu","year":"2016","unstructured":"Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol. 2016;8:48\u201356. https:\/\/doi.org\/10.1177\/1758834015616934.","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"4209_CR89","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/JAMADERMATOL.2024.0390","volume":"160","author":"P Aggarwal","year":"2024","unstructured":"Aggarwal P, Clark D, Shah A, Rismiller K, Neltner SA. Keratoacanthoma and cutaneous squamous cell carcinoma with PD-1 and PD-L1 inhibitor use. JAMA Dermatol. 2024;160(5):573\u20135. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2024.0390.","journal-title":"JAMA Dermatol"},{"key":"4209_CR90","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1001\/ARCHDERM.144.6.820","volume":"144","author":"HH Kong","year":"2008","unstructured":"Kong HH, Sibaud V, Chanco Turner ML, Fojo T, Hornyak TJ, Chevreau C. Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol. 2008;144:820\u20132. https:\/\/doi.org\/10.1001\/ARCHDERM.144.6.820.","journal-title":"Arch Dermatol"},{"key":"4209_CR91","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","volume":"30","author":"L Zimmer","year":"2012","unstructured":"Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30:2375\u201383. https:\/\/doi.org\/10.1200\/JCO.2011.41.1660.","journal-title":"J Clin Oncol"},{"key":"4209_CR92","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/JAMADERMATOL.2013.21","volume":"149","author":"S Dalle","year":"2013","unstructured":"Dalle S, Poulalhon N, Debarbieux S, Zaharia D, Mihm MC, Lacouture ME, et al. Tracking of second primary melanomas in vemurafenib-treated patients. JAMA Dermatol. 2013;149:488\u201390. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2013.21.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"4209_CR93","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJMOA2210140","volume":"388","author":"M Gounder","year":"2023","unstructured":"Gounder M, Ratan R, Alcindor T, Sch\u00f6ffski P, van der Graaf WT, Wilky BA, et al. Nirogacestat, a \u03b3-secretase inhibitor for desmoid tumors. N Engl J Med. 2023;388(10):898\u2013912. https:\/\/doi.org\/10.1056\/NEJMOA2210140.","journal-title":"N Engl J Med"},{"key":"4209_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2023-007675","author":"ST Chen","year":"2024","unstructured":"Chen ST, Semenov YR, Alloo A, Bach DQ, Betof Warner A, Bougrine A, et al. Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/JITC-2023-007675.","journal-title":"J Immunother Cancer"},{"key":"4209_CR95","unstructured":"CTEP Trial Development and Conduct - NCI . [cited 2025 Aug 28]. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/trial-development. Accessed 28 Aug 2025"},{"key":"4209_CR96","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.001.","journal-title":"Cancer Treat Rev"},{"key":"4209_CR97","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1200\/JCO.18.02141","volume":"37","author":"GS Phillips","year":"2019","unstructured":"Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, et al. Treatment outcomes of immune-related cutaneous adverse events. J Clin Oncol. 2019;37:2746\u201358. https:\/\/doi.org\/10.1200\/JCO.18.02141.","journal-title":"J Clin Oncol"},{"key":"4209_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/S40425-017-0300-Z","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017. https:\/\/doi.org\/10.1186\/S40425-017-0300-Z.","journal-title":"J Immunother Cancer"},{"key":"4209_CR99","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/JAMADERMATOL.2016.2226","volume":"152","author":"VJ Shi","year":"2016","unstructured":"Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, et al. Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol. 2016;152:1128\u201336. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2016.2226.","journal-title":"JAMA Dermatol"},{"key":"4209_CR100","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2021-003066","author":"BR Halle","year":"2021","unstructured":"Halle BR, Betof Warner A, Zaman FY, Haydon A, Bhave P, Dewan AK, et al. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/JITC-2021-003066.","journal-title":"J Immunother Cancer"},{"key":"4209_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2020.588582","author":"CD Sadik","year":"2021","unstructured":"Sadik CD, Langan EA, Gutzmer R, Fleischer MI, Loquai C, Reinhardt L, et al. Retrospective analysis of checkpoint inhibitor therapy-associated cases of bullous pemphigoid from six German dermatology centers. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/FIMMU.2020.588582.","journal-title":"Front Immunol"},{"key":"4209_CR102","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/BJD\/LJAE403","volume":"192","author":"N Planella-Fontanillas","year":"2025","unstructured":"Planella-Fontanillas N, Bosch-Amate X, Ant\u00f3n AJ, Moreno-V\u00edlchez C, Guerrero MG, Blanes Mart\u00ednez MdelM, et al. Real-world evaluation of the effectiveness and safety of dupilumab in bullous pemphigoid: an ambispective multicentre case series. Br J Dermatol. 2025;192:501\u20139. https:\/\/doi.org\/10.1093\/BJD\/LJAE403.","journal-title":"Br J Dermatol"},{"key":"4209_CR103","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/AJD.14262","volume":"65","author":"H Godfrey","year":"2024","unstructured":"Godfrey H, Jedlowski P, Thiede R. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: a case\/non-case analysis using the Food and Drug Administration Adverse Event Reporting System. Australas J Dermatol. 2024;65:243\u201353. https:\/\/doi.org\/10.1111\/AJD.14262.","journal-title":"Australas J Dermatol"},{"key":"4209_CR104","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5376476","author":"CY Ng","year":"2018","unstructured":"Ng CY, Chen CB, Wu MY, Wu J, Yang CH, Hui RCY, et al. Anticancer drugs induced severe adverse cutaneous drug reactions: an updated review on the risks associated with anticancer targeted therapy or immunotherapies. J Immunol Res. 2018. https:\/\/doi.org\/10.1155\/2018\/5376476.","journal-title":"J Immunol Res"},{"key":"4209_CR105","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2147\/CMAR.S163391","volume":"10","author":"CB Chen","year":"2018","unstructured":"Chen CB, Wu MY, Ng CY, Lu CW, Wu J, Kao PH, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res. 2018;10:1259\u201373. https:\/\/doi.org\/10.2147\/CMAR.S163391.","journal-title":"Cancer Manag Res"},{"key":"4209_CR106","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/JDV.16894","volume":"35","author":"I Torres-Navarro","year":"2021","unstructured":"Torres-Navarro I, de Unamuno-Bustos B, Botella-Estrada R. Systematic review of BRAF\/MEK inhibitors-induced severe cutaneous adverse reactions (SCARs). J Eur Acad Dermatol Venereol. 2021;35:607\u201314. https:\/\/doi.org\/10.1111\/JDV.16894.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4209_CR107","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27747","volume":"66","author":"TP Miller","year":"2019","unstructured":"Miller TP, Fisher BT, Getz KD, Sack L, Razzaghi H, Seif AE, et al. Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events. Pediatr Blood Cancer. 2019;66:e27747. https:\/\/doi.org\/10.1002\/pbc.27747.","journal-title":"Pediatr Blood Cancer"},{"key":"4209_CR108","unstructured":"U.S. Department of Health and Human Services (2017) Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. Cancer Therapy Evaluation Program (CTEP). 155."},{"key":"4209_CR109","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00520-009-0744-x","volume":"18","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer. 2010;18:509\u201322. https:\/\/doi.org\/10.1007\/s00520-009-0744-x.","journal-title":"Support Care Cancer"},{"key":"4209_CR110","unstructured":"https:\/\/mascc.org\/wp-content\/uploads\/2022\/04\/mestt.pdf."},{"key":"4209_CR111","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s00520-010-0999-2","volume":"19","author":"A Chan","year":"2011","unstructured":"Chan A, Tan EH. How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Support Care Cancer. 2011;19:1667\u201374. https:\/\/doi.org\/10.1007\/s00520-010-0999-2.","journal-title":"Support Care Cancer"},{"key":"4209_CR112","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-07793-5","volume":"31","author":"S Gu","year":"2023","unstructured":"Gu S, Menzer C, Hay JL, Pena C, Dusza S, Lacouture ME, et al. PRO-CTCAE reveals under-recognition of dermatologic symptom burden in hospitalized cancer patients. Support Care Cancer. 2023;31:337. https:\/\/doi.org\/10.1007\/s00520-023-07793-5.","journal-title":"Support Care Cancer"},{"key":"4209_CR113","unstructured":"https:\/\/who-umc.org\/whodrug\/"},{"key":"4209_CR114","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up \u2606. Ann Oncol. 2022;33:1217\u201338. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001.","journal-title":"Ann Oncol"},{"key":"4209_CR115","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/JAMADERMATOL.2020.1794","volume":"156","author":"BY Kwong","year":"2020","unstructured":"Kwong BY. Outcomes of embedding dermatologic care within oncology practices for patients with cancer. JAMA Dermatol. 2020;156:1051\u20132. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2020.1794.","journal-title":"JAMA Dermatol"},{"key":"4209_CR116","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1111\/JDV.20282","volume":"39","author":"D Fattore","year":"2025","unstructured":"Fattore D, Lauletta G, Apalla Z, Sibaud V, Freites-Martinez A. Dermatologic immune-related adverse events: it is time for a game change! J Eur Acad Dermatol Venereol. 2025;39:e271\u20132. https:\/\/doi.org\/10.1111\/JDV.20282.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"4209_CR117","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1111\/JDV.19679","volume":"38","author":"A Freites-Martinez","year":"2024","unstructured":"Freites-Martinez A, Apalla Z, Fattore D, Fida M, Bang AS, Smith J, et al. Supportive oncodermatology practices in Europe and the USA. J Eur Acad Dermatol Venereol. 2024;38(5):e440\u20133. https:\/\/doi.org\/10.1111\/JDV.19679.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4209_CR118","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1002\/IJC.30691","volume":"140","author":"Z Yang","year":"2017","unstructured":"Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, et al. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: a meta-analysis. Int J Cancer. 2017;140:2805\u201319. https:\/\/doi.org\/10.1002\/IJC.30691.","journal-title":"Int J Cancer"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04209-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04209-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04209-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:57:44Z","timestamp":1781873864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04209-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":118,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4209"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04209-0","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MM reports honoraria from Amgen, AstraZeneca, Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Pfizer, Boehringer Ingelheim, Novartis, Immedica, Helsinn Therapeutics, Takeda, Sanofi, Johnson & Johnson, Pierre Fabre, Beigene, Lilly; Research Funding from Bristol-Myers Squibb (Inst), AstraZeneca (Inst), Roche (Inst); travel, accommodations from AstraZeneca, Roche, Pfizer, MSD, Johnson & Johnson. FdAAA reports holding a consultant role at Pfizer and Boehringer Inghelheim, being a speaker for Astra Zeneca, Takeda, and Sanofi, receiving travel expenses from Janssen, Gallecto, Pfizer, Roche, MSD, and Takeda; and others (GIDO). CC reports having received honoraria for speaking for La Roche Posay, ISD, Jonhson and Johnson, as well as travel grants from SANOFI, Pierre Fabre, ISDIN, and BMS. AF-M received support for attending meetings and\/or travel from J&J Spain, ISDIN Spain, Galderma Spain; consultancy from SHB Law Firm\u2013Sanofi; and honoraria\/educational support from J&J Spain, ISDIN Spain, Galderma Spain, and SHB Law Firm\u2013Sanofi. OS reports being a consultant for Johnson and Johnson, Regeneron, Roche Pharma, Sunpharma and Cantabria Labs. ABC, AMI, KMM, CR, and MZP, have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All patients gave informed consent for the publication of their images that illustrate this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}